|
Priyanka's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Setara Biosciences secured $90 million for its rare disease pipeline, BridgeBio awaits an FDA decision on a muscular dystrophy therapy, and Abbott reported strong trial results.
The top 10 stories from Fri Oct 30, 2026 07:06 AM to Mon Nov 2, 2026 07:07 AM
Generated November 2, 2026 at 7:07 AM
|
|
|
#1 Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial. Published 2026-10-31 Zhimeng Biopharma completed patient enrollment in the pivotal Phase 2/3 trial of its investigational ALS drug, CB03-154. Covered by: prnewswire.com |
#2 INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) Published 2026-10-30 The FDA granted accelerated approval to INOVIO’s VOCERYQ, a plasmid DNA immunotherapy targeting HPV-6 and HPV-11 to reduce surgery frequency in adults with recurrent respiratory papillomatosis. Covered by: prnewswire.com, fda.gov |
#3 BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight Published 2026-11-02 The FDA is expected to decide by Nov. 27 whether to approve BridgeBio Pharma’s BBP-418, which could become the first therapy for limb-girdle muscular dystrophy. Covered by: biospace.com |
#4 Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System Published 2026-11-01 Abbott reported strong 30-day outcomes and high procedural success in the TECTONIC trial of its investigational SonicForce coronary lithotripsy system. Covered by: prnewswire.com |
#5 At least 11 PDUFAs on FDA’s November docket Published 2026-10-31 The FDA’s November docket includes at least 11 PDUFA dates, with PD-1/VEGF bispecific ivonescimab first on the schedule. Covered by: biocentury.com |
#6 US FDA’s November Calendar Pairs Big Oncology Bets With Potential Rare Disease Firsts Published 2026-10-30 The FDA’s November user-fee calendar includes 14 novel agents, spanning oncology candidates and potential first treatments for rare diseases. Covered by: insights.citeline.com |
#7 Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back Published 2026-10-30 Gilead paused a CAR-T program after several cases of ICANS, while the FDA delayed Agios’ PDUFA date. Covered by: endpoints.news |
#8 Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal Published 2026-10-30 Setara Biosciences spun out Actio Biosciences’ remaining genetics-driven pipeline after its epilepsy drug deal with Jazz Pharmaceuticals and secured $90 million in new funding. Covered by: endpoints.news, fiercebiotech.com, biospace.com |
#9 New clinical data on lecanemab to be presented at CTAD conference 2026 Published 2026-10-30 Eisai will present new clinical and real-world evidence on lecanemab at the Clinical Trials on Alzheimer’s Disease conference in Boston, November 16–19, 2026. Covered by: prnewswire.com, prnewswire.com |
#10 New EU Filings Published 2026-10-30 Immunome has filed varegacestat, a treatment for adults with desmoid tumors, with the European Medicines Agency for potential EU marketing approval. Covered by: insights.citeline.com |
